ID   IGR-HEU
AC   CVCL_A2BA
SY   IGR-Heu; Institut Gustave Roussy-HEU
DR   cancercelllines; CVCL_A2BA
DR   IARC_TP53; 21659
DR   Wikidata; Q105509642
RX   PubMed=9639386;
RX   PubMed=15634909;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Unspecified (PubMed=15634909).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 6
//
RX   PubMed=9639386; DOI=10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-y;
RA   Asselin-Paturel C., Echchakir H., Carayol G., Gay F., Opolon P.,
RA   Grunenwald D., Chouaib S., Mami-Chouaib F.;
RT   "Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression
RT   in tumor, TIL and PBL of non-small cell lung cancer patients.";
RL   Int. J. Cancer 77:7-12(1998).
//
RX   PubMed=15634909; DOI=10.4049/jimmunol.174.2.871;
RA   Thiery J., Abouzahr S., Dorothee G., Jalil A., Richon C., Vergnon I.,
RA   Mami-Chouaib F., Chouaib S.;
RT   "p53 potentiation of tumor cell susceptibility to CTL involves Fas and
RT   mitochondrial pathways.";
RL   J. Immunol. 174:871-878(2005).
//